BioSante Pharmaceuticals to Present at Upcoming Healthcare Conferences
LINCOLNSHIRE, Illinois (September 2, 2009) – BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced that Stephen M. Simes, its president and CEO will present an overview of the company and its impending merger with Cell Genesys (NASDAQ: CEGE) at two healthcare investment and partnering conferences during the month of September.
The conference presentation schedule is as follows:
Rodman and Renshaw Annual Global Investment Conference
September 10, 2009 at 11:15 am
The New York Palace Hotel
BioPharm America Conference
September 17, 2009 at 2:45 pm
Information about the conference is available at http://www.ebdgroup.com/bpa/
A live audio webcast of BioSante’s presentation at the Rodman and Renshaw conference. A replay will be available at the same link.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. BioSante’s lead products include LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment) for the treatment of female sexual dysfunction (FSD), and Elestrin™ (estradiol gel) developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, currently marketed in the U.S.
Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3 billion. Under BioSante’s license agreement with Antares Pharma, BioSante is required to pay Antares a portion of the royalties, license and milestone payments received for products covered by that agreement. The company also is developing its calcium phosphate technology (CaP) for novel vaccines, drug delivery and aesthetic medicine (BioLook™). Additional information is available online at: biosantepharma.cdmail.biz.
For more information please contact:
Harris D. McKinney, Inc.